Celldex Therapeutics

CLDX Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$31.06

-0.64% today

52W: $14.40 – $34.52

52W Low: $14.40 Position: 82.8% 52W High: $34.52

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

1338.22x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$2.1B

Market Capitalization

Revenue Growth

-89.7%

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-40.62%

Return on Equity

Beta

1.2

Market sensitivity

Short Interest

16.39%

% of float sold short

Avg. Volume

944,545

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

15 analysts

Avg. Price Target

$54.33

+74.93% upside

Target Range

$24.00 – $90.00

About the Company

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic str

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 198 Exchange: NCM